Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours

dc.contributor.authorZurita, A. J.
dc.contributor.authorDiestra, J. E.
dc.contributor.authorCondom i Mundó, Enric
dc.contributor.authorGarcía del Muro Solans, Xavier
dc.contributor.authorScheffer, G. L.
dc.contributor.authorScheper, R. J.
dc.contributor.authorPérez, J.
dc.contributor.authorGermà Lluch, José Ramón
dc.contributor.authorIzquierdo, M. A.
dc.date.accessioned2018-03-13T10:54:50Z
dc.date.available2018-03-13T10:54:50Z
dc.date.issued2003-03-24
dc.date.updated2018-03-13T10:54:50Z
dc.description.abstractThis study was undertaken to investigate the expression and predictive value for outcome of multidrug resistance-associated (MDR) proteins P-glycoprotein (Pgp), MRP1, BCRP, and LRP, in advanced testicular germ-cell tumours (TGCT). Paraffin-embedded sections from 56 previously untreated patients with metastatic TGCT were immunostained for Pgp, MRP1, BCRP, and LRP. All patients received platinum-based chemotherapy after orchidectomy. Immunostaining was related to clinicopathological parameters, response to chemotherapy, and outcome. Strong and intermediate expressions of the different MDR-related proteins were: 27 and 41% (Pgp), 54 and 37% (MRP1), 86 and 7% (BCRP), and 14 and 29% (LRP). P-glycoprotein and MRP1 associated, respectively, to low AFP (P=0.026) and high LDH levels (P=0.014), whereas LRP expression associated with high β-hCG levels (P=0.003) and stage IV tumours (P=0.029). No correlation was found between Pgp, MRP1, and BCRP expression and response to chemotherapy and survival. In contrast, patients with LRP-positive tumours (strong or intermediate expression) had shorter progression-free (P=0.0006) and overall survival (P=0.0116) than LRP-negative patients, even after individual log-rank adjustments by statistically associated variables. Our data suggest that a positive LRP immunostaining at the time of diagnosis in metastatic TGCT is associated with an adverse clinical outcome.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec524876
dc.identifier.issn0007-0920
dc.identifier.pmid12644825
dc.identifier.urihttps://hdl.handle.net/2445/120651
dc.language.isoeng
dc.publisherCancer Research UK
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/sj.bjc.6600803
dc.relation.ispartofBritish Journal of Cancer, 2003, vol. 88, num. 6, p. 879-886
dc.relation.urihttps://doi.org/10.1038/sj.bjc.6600803
dc.rightscc-by-nc-sa (c) Zurita, A. J. et al., 2003
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationMalalties del testicle
dc.subject.classificationCèl·lules germinals
dc.subject.classificationTumors
dc.subject.classificationExpressió gènica
dc.subject.classificationProteïnes supressores de tumors
dc.subject.classificationResistència als medicaments
dc.subject.otherTestis diseases
dc.subject.otherGerm cells
dc.subject.otherTumors
dc.subject.otherGene expression
dc.subject.otherTumor suppressor protein
dc.subject.otherDrug resistance
dc.titleLung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
524876.pdf
Mida:
197.12 KB
Format:
Adobe Portable Document Format